Cisplatin

Generic Name
Cisplatin
Brand Names
Platinol
Drug Type
Small Molecule
Chemical Formula
Cl2H6N2Pt
CAS Number
15663-27-1
Unique Ingredient Identifier
Q20Q21Q62J
Background

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

First Posted Date
2003-01-27
Last Posted Date
2013-06-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
50
Registration Number
NCT00041106
Locations
🇺🇸

Cancer and Leukemia Group B, Chicago, Illinois, United States

Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

First Posted Date
2003-01-27
Last Posted Date
2013-06-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
78
Registration Number
NCT00047047
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer

Phase 2
Completed
Conditions
Kidney Cancer
First Posted Date
2003-01-27
Last Posted Date
2010-06-11
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
32
Registration Number
NCT00003928
Locations
🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura

Phase 3
Completed
Conditions
Malignant Mesothelioma
First Posted Date
2003-01-27
Last Posted Date
2012-07-18
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
256
Registration Number
NCT00004920
Locations
🇬🇧

Western General Hospital, Edinburgh, Scotland, United Kingdom

🇧🇪

U.Z. Gasthuisberg, Leuven, Belgium

🇵🇱

Regional Lung Diseases Hospital, Poznan, Poland

and more 23 locations

Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed

Phase 3
Terminated
Conditions
Lung Cancer
First Posted Date
2003-01-27
Last Posted Date
2012-07-18
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
158
Registration Number
NCT00003803
Locations
🇳🇱

Radiotherapeutisch Instituut-(Riso), Deventer, Netherlands

🇳🇱

Sophia Ziekehuis, Zwolle, Netherlands

🇳🇱

Antoni van Leeuwenhoekhuis, Amsterdam, Netherlands

and more 14 locations

Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas

Phase 3
Completed
Conditions
Pancreatic Cancer
First Posted Date
2003-01-27
Last Posted Date
2012-07-02
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
200
Registration Number
NCT00003029
Locations
🇫🇷

Centre Hospitalier de la Cote Basque, Bayonne, France

🇫🇷

Hopital Perpetuel Secours, Levallois-Perret, France

🇧🇪

Les Cliniques Saint-Joseph ASBL, Liege, Belgium

and more 16 locations

Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Phase 3
Completed
Conditions
Lung Cancer
First Posted Date
2003-01-27
Last Posted Date
2012-07-02
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
640
Registration Number
NCT00002623
Locations
🇳🇱

Ziekenhuis St Jansdal, Harderwijk, Netherlands

🇬🇧

Royal Marsden Hospital, Sutton, England, United Kingdom

🇧🇪

Algemeen Ziekenhuis Middelheim, Antwerp, Belgium

and more 27 locations

S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat

First Posted Date
2003-01-27
Last Posted Date
2012-06-14
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
13
Registration Number
NCT00017173
Locations
🇺🇸

Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States

🇺🇸

Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States

🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer

First Posted Date
2003-01-27
Last Posted Date
2009-04-30
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
30
Registration Number
NCT00004063
Locations
🇺🇸

University of Texas Health Science Center at Houston, Houston, Texas, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer

Phase 1
Completed
Conditions
Esophageal Cancer
Gastric Cancer
First Posted Date
2003-01-27
Last Posted Date
2013-06-19
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00005638
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy